JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth
about
MPNs as Inflammatory Diseases: The Evidence, Consequences, and PerspectivesThe Role of Reactive Oxygen Species in Myelofibrosis and Related NeoplasmsDynamic aberrant NF-κB spurs tumorigenesis: a new model encompassing the microenvironmentCD45 phosphatase is crucial for human and murine acute myeloid leukemia maintenance through its localization in lipid raftsVirtual pathway explorer (viPEr) and pathway enrichment analysis tool (PEANuT): creating and analyzing focus networks to identify cross-talk between molecules and pathways.The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.Analytical use of multi-protein Fluorescence Resonance Energy Transfer to demonstrate membrane-facilitated interactions within cytokine receptor complexesStatin use is associated with reduced risk of haematological malignancies: evidence from a meta-analysis.Are MPNs vascular diseases?Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms.A remarkable hematological and molecular response pattern in a patient with polycythemia vera during combination therapy with simvastatin and alendronate.Simvastatin induced actin cytoskeleton disassembly in normal and transformed fibroblasts without affecting lipid raft integrity.Perspectives on the increased risk of second cancer in patients with essential thrombocythemia, polycythemia vera and myelofibrosis.Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide.Pro-metastatic signaling of the trans fatty acid elaidic acid is associated with lipid rafts.
P2860
Q26775996-C25302DD-5901-4FEA-88F7-A792A9E38FF3Q26779929-79B65812-7FA1-4620-8012-A3A062092CBDQ27025321-0C60A9C0-A2A4-4ABC-A261-E606FE7058C5Q28278205-7F8735E8-B07A-4FD0-95E5-F24860444121Q35807564-07691C7D-A69F-4659-BA6B-4C631EC48CFEQ36545566-94836969-C540-4891-B5EB-B965F573052DQ37164852-1519EC70-B934-4317-B0F6-62AF1CC7F5B6Q37538571-0DB9FA06-0BED-43A2-B91C-D45CBA39D561Q38137750-C2E41E6D-FA49-4D58-B7AF-22C8821DF2E9Q38187674-6E874D18-7914-4255-BB4B-33A1DEF43B1AQ41882404-4EB0F73F-B278-4B74-82A2-505B8CDB85BDQ42799535-3C00EBF2-2C08-4AB6-9263-CA9091B308B4Q53680800-E4BF30A9-6369-4897-ADE6-7D455C084CD1Q54282327-76032591-B027-4FD9-B901-1071012943E2Q55404108-BA0AD793-FF2A-4046-9F7B-FDB5AE573B17
P2860
JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
JAK2-V617F-mediated signalling ...... K2-V617F-dependent cell growth
@ast
JAK2-V617F-mediated signalling ...... K2-V617F-dependent cell growth
@en
type
label
JAK2-V617F-mediated signalling ...... K2-V617F-dependent cell growth
@ast
JAK2-V617F-mediated signalling ...... K2-V617F-dependent cell growth
@en
prefLabel
JAK2-V617F-mediated signalling ...... K2-V617F-dependent cell growth
@ast
JAK2-V617F-mediated signalling ...... K2-V617F-dependent cell growth
@en
P2093
P2860
P356
P1476
JAK2-V617F-mediated signalling ...... K2-V617F-dependent cell growth
@en
P2093
Gary W Reuther
Joseph O Johnson
Kathy L McGraw
Lori N Griner
P2860
P304
P356
10.1111/BJH.12103
P407
P50
P577
2012-11-15T00:00:00Z